Mayne Pharma Group Limited (ASX:MYX) held its 2026 Annual General Meeting on 20 November 2026 in Melbourne, with Chair Professor Bruce Robinson disclosing group revenue of $383.7 million for FY26, a net profit after tax of $31.2 million compared with a net loss of $90.1 million in FY25, and significant changes at both board and management level during the year.
Key Points
- FY26 group revenue of $383.7 million, down 6% on FY25, with gross profit of $248.2 million held flat on the prior year
- Group gross margin expanded to 64.7% from 60.6% in FY25, with branded products representing 83% of net sales
- Net profit after tax of $31.2 million recorded for FY26, compared with a net loss of $90.1 million in FY25
- Cash and marketable securities stood at $80.0 million at 30 June 2026, including recovery of $14.4 million in legal costs and interest from Cosette
- Meghan Rivera and Jacob Ma-Weaver joined the board in June and August 2026 respectively, standing for election at today's meeting
FY26 Financial Results Disclosed at AGM
According to the Chair's address, Mayne Pharma generated group revenue of $383.7 million in FY26, down 6% on FY25. Gross profit of $248.2 million was held flat on the prior year, with group gross margin expanding to 64.7% from 60.6% in FY25. Total direct segment contribution was $107.1 million, down 2% on the prior year. Underlying EBITDA was $34.2 million, down 27%, after absorbing increased investment in Women's Health sales and marketing, higher post-market study costs, unfavourable foreign exchange movements and payment of short-term incentives not paid in FY25. Adjusted operating cash flow from continuing operations was $34.5 million.
Board and Management Changes During FY26
The filing disclosed that Pat Blake and Anne Lockwood retired as non-executive directors following the release of first half results in February 2026, and Dr Katie MacFarlane stepped down at the end of May 2026. Meghan Rivera joined the board in June 2026, bringing more than 25 years' experience in the US pharmaceutical industry, including senior roles at Organon and AMAG Pharmaceuticals. Jacob Ma-Weaver joined the board on 14 August 2026 as Managing Member of Cable Car Capital, with Funicular Funds holding 9.82% of the company's shares. At management level, Shawn O'Brien stepped down as Managing Director and CEO on 20 February 2026, with Aaron Gray appointed CEO with immediate effect. Griffin Buchanan commenced as Chief Financial Officer on 1 August 2026, bringing more than 19 years at Siemens Healthineers.
Women's Health Segment and NEXTSTELLIS Performance
The Chair's address disclosed that NEXTSTELLIS®, described as the only oral contraceptive in the US containing estetrol and protected by Orange Book patents to 2043, delivered demand cycle growth of 15% and US net sales of US$45.2 million during FY26. BIJUVA® recorded total prescription growth of 26% following the removal of an FDA black box warning. The filing also noted that the DistributeRx platform was launched during the year as a strategic initiative. The company's cash and marketable securities position of $80.0 million at 30 June 2026 was supported by the recovery of $14.4 million in legal costs and interest from Cosette in June 2026.





Please wait processing your request...